TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
31/12/2024
Voltar para busca
Dado oficial do USPTO
CELLFE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
31/12/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 10
Data de depósito
23/03/2020
Data de registro
14/12/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/12/2021
Última transação
31/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
09/08/2021
Primeiro uso no comércio
09/08/2021
Código do desenho
4
Tipo de titular
03
Localização do titular
Alameda, CA
Examinador
KEAN, AMY C
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
CELLFE, INC.
Representantes
Vladimir Y. Gusev Polygon IP, LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Therapeutic pharmaceuticals for changing immune response and improving regenerative capacities for use in the treatment of medical conditions and diseasescancerblood diseasesinfectious diseasesautoimmune diseases; Therapeutic pharmaceuticals for changing immune response and improving regenerative capacities for the prevention of medical conditions and diseasescancerblood diseasesinfectious diseasesautoimmune diseases; Living cells for treating medical conditions and diseasescancerblood diseasesinfectious diseasesautoimmune diseases; Living cells for medical purposesfor creating cell therapies
Classe 9
Laboratory apparatus in the nature of microfluidic chips for scientific research for use in the delivery of macromoleculesnanoparticlespolymers to cells; Laboratory apparatus kits comprising microfluidic chips and a pressurized gas system comprised of flow control instrumentsgas supplyflow channelscontainersvessels for scientific research; Laboratory apparatus kits comprising microfluidic chips and pumping systems comprised of flow control instrumentsflow pumpsflow channelscontainersvessels for scientific research
Classe 10
Medical apparatus in the nature of microfluidic chips for use in cell therapy and immunotherapy for use in the delivery of macromoleculesnanoparticles and polymers to cells; Medical apparatus in the nature of a kit comprising microfluidic chipsa control apparatusa pressurized gas system comprised of flow control instrumentsgas supplyflow channelscontainersvessels for delivery of cell therapyimmunotherapymedical treatmentsdiagnostics; Medical equipment in the nature of a kit comprising microfluidic chipsa control apparatusa pumping system comprised of flow control instrumentsflow pumpsflow channelscontainersvessels for delivery of cell therapyimmunotherapymedical treatmentsdiagnostics; Medical instruments in the nature of a medical kit comprising disposable microfluidic chipsdisposable tubing and disposable containers for medical purposesgenerating cells to treat cancerblood diseasesinfectious diseasesautoimmune diseases all for use in cell therapy and immunotherapy medical treatments
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
31/12/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
31/12/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
14/12/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/11/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/11/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/10/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/10/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/10/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
16/10/2021
GNRT
NON-FINAL ACTION E-MAILED
16/10/2021
CNRT
SU - NON-FINAL ACTION - WRITTEN
16/10/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
27/09/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
27/09/2021
IUAF
USE AMENDMENT FILED
15/09/2021
EISU
TEAS STATEMENT OF USE RECEIVED
15/09/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
16/03/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/01/2021
PUBO
PUBLISHED FOR OPPOSITION
19/01/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/12/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/12/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
16/12/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/12/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
16/12/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
16/12/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/11/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/11/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/11/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
15/06/2020
GNRT
NON-FINAL ACTION E-MAILED
15/06/2020
CNRT
NON-FINAL ACTION WRITTEN
15/06/2020
DOCK
ASSIGNED TO EXAMINER
14/06/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/03/2020
NWAP
NEW APPLICATION ENTERED
26/03/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELLFE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.